{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06504368",
            "orgStudyIdInfo": {
                "id": "DCR-PDL1-101"
            },
            "organization": {
                "fullName": "Novo Nordisk A/S",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors",
            "officialTitle": "An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-PDL1 in Adults With Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "safety-tolerability-and-pharmacokinetics-of-dcr-in-adults-with-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-05-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-18",
            "studyFirstSubmitQcDate": "2024-07-10",
            "studyFirstPostDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumors, Adult"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "DCR-PDL1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive multiple IV doses of DCR-PDL1 during each treatment cycle.",
                    "interventionNames": [
                        "Drug: DCR-PDL1"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "DCR-PDL1",
                    "description": "Solution for IV Infusion",
                    "armGroupLabels": [
                        "DCR-PDL1"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and Nature of Adverse Events (AEs)",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Incidence of Dose-limiting Toxicities (DLTs)",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change From Baseline in Vital Signs: Oral, Tympanic, Temporal Artery Temperature",
                    "description": "Vital signs will be measured in a semi-supine (i.e., semi-recumbent) position.",
                    "timeFrame": "Baseline up to week 8"
                },
                {
                    "measure": "Change From Baseline in Vital Signs: Systolic and Diastolic Blood Pressure",
                    "description": "Vital signs will be measured in a semi-supine (i.e., semi-recumbent) position.",
                    "timeFrame": "Baseline up to week 8"
                },
                {
                    "measure": "Change From Baseline in Vital Signs: Pulse and Respiratory Rate",
                    "description": "Vital signs will be measured in a semi-supine (i.e., semi-recumbent) position. Blood pressure and pulse measurements should be preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.",
                    "timeFrame": "Baseline up to week 8"
                },
                {
                    "measure": "Change from Baseline in 12-lead Electrocardiogram (ECG): Heart Rate and Pulse Rate",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in 12-lead Electrocardiogram (ECG): QRS intervals",
                    "description": "ECG recordings will be made in a semi-supine (i.e., semi-recumbent) position, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in 12-lead Electrocardiogram (ECG): QT intervals",
                    "description": "ECG recordings will be made in a semi-supine (i.e., semi-recumbent) position, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in 12-lead Electrocardiogram (ECG): QTcF intervals (QT Interval Corrected by the Fridericia Formula)",
                    "description": "ECG recordings will be made in a semi-supine (i.e., semi-recumbent) position, preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Hematology Parameter: Red blood cells, White blood cells, Lymphocytes, Monocytes, Eosinophils, Neutrophils, Basophils and Platelets, Reticulocytes",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Hematology Parameter: Mean corpuscular volume (MCV)",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Hematology Parameter: Mean corpuscular hemoglobin (MCH)",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Hematology Parameter: Hemoglobin",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Hematology Parameter: Hematocrit and Mean corpuscular hemoglobin concentration (MCHC)",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Coagulation Parameter: International normalized ratio (INR)",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Coagulation Parameter: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT)",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Coagulation Parameter: Fibrinogen",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Clinical Chemistry Parameter: Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma-glutamyl transferase (GGT), Alkaline phosphatase (ALP), Lactate dehydrogenase (LDH) and Creatine kinase (CK)",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Clinical Chemistry Parameter: Total protein and Albumin",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Clinical Chemistry Parameter: Total bilirubin, Direct bilirubin, Fasting blood glucose, Creatinine and Blood urea nitrogen (BUN)",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Clinical Chemistry Parameter: Sodium, Chloride and Potassium",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Urinalysis Parameter: Glucose, Protein, Bilirubin and Urobilinogen",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Urinalysis Parameter: Specific Gravity",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Urinalysis Parameter: Potential of Hydrogen (pH) of Urine",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Urinalysis Parameter: Blood",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Urinalysis Parameter: Ketones and Nitrite",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Change from Baseline in Urinalysis Parameter: Leukocyte esterase",
                    "timeFrame": "Baseline to week 8"
                },
                {
                    "measure": "Number of Participants with Change from Baseline in Physical Examination Findings: Cardiovascular, Respiratory, Gastrointestinal, and Neurological systems",
                    "description": "A complete physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, gastrointestinal, and neurological systems.",
                    "timeFrame": "Baseline to week 8"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Pharmacokinetic Plasma Concentrations of DCR-PDL1",
                    "timeFrame": "Pre-dose up to 48 hours post-dose"
                },
                {
                    "measure": "Pharmacokinetic Urine Concentrations of DCR-PDL1",
                    "timeFrame": "Up to 8 hours post-dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female adults, aged greater than or equal to (\u2265) 18 years.\n* Participants are required to have a documented, locally advanced or metastatic solid tumor malignancy, or non-Hodgkin's lymphoma\n\n  * that is refractory to standard therapy known to provide clinical benefit for their condition OR\n  * have demonstrated evidence of disease progression or relapse, via imaging, during or following standard therapy known to provide clinical benefit for their condition, OR\n  * have demonstrated intolerance to standard therapy known to provide clinical benefit for their condition. OR\n  * for which no standard therapy is available\n* Measurable disease according to RECIST version 1.1.\n* Malignancy not currently amenable to surgical intervention.\n* ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of \u2265 3 months at the time of signing the informed consent.\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Participants with known CNS or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required.\n* Other protocol defined exclusion criteria could apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Vinita Uttamsingh",
                    "role": "CONTACT",
                    "phone": "+1 617-621-8097"
                }
            ],
            "locations": [
                {
                    "facility": "Next Oncology",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}